VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 ...

INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian ...

Fast Track designation highlights potential of INX-315 to address unmet need for patients with recurrent advanced/metastatic ...

Part 2a is designed to confirm the primary dose-of-interest with a target enrollment of approximately 30 patients at each of two dose levels: 400mg QD 5:2 and 300mg QD 5:2 (intermittent daily dosing ...

In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers.

WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent ... for patients with Cyclin E1+ platinum-resistant ...

Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors Circle Pharma, a clinical-stage biopharmaceutical company focused on ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Protein Kinase A (PKA) is regulated spatially ...

CDK1 和 CDK2 的 G x G xx G 基序中的酪氨酸 15，其磷酸化会下调催化活性，这在 CHPK 的相应基序中是保守的。研究发现，单纯疱疹病毒 2 型（HSV-2）中的 CHPK UL13，其对应 Tyr-162 在 HSV-2 感染的细胞中会被磷酸化。对 HSV-2 UL13 Tyr-162 的突变分析表明，UL13 Tyr-162 的磷酸化会 ...